Advertisement

Topics

Neurovance, Inc. Company Profile

02:53 EDT 23rd June 2017 | BioPortfolio

Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.


News Articles [20 Associated News Articles listed on BioPortfolio]

Neurovance to be acquired by Otsuka

Neurovance will be purchased by Otsuka Pharmaceutical, giving the latter rights to Neurovance's centanafadine, a treatment f -More- 

Neurovance accepts takeover bid from Otsuka

Privately-held US firm Neurovance, which is focused on attention-deficit hyperactivity disorder (ADHD)…

Otsuka to Buy Neurovance for up to $250M to acquire Phase III-ready ADHD Drug

Otsuka Pharmaceutical has agreed a potentially $250 million deal to buy Neurovance so that it can acquire the firm’s Phase III-ready attention-deficit hyperactivity disorder (ADHD) drug, centanafadi...

Otsuka to acquire Neurovance in potential $250 million deal

Otsuka Pharmaceuticals, a pharmaceutical firm with headquarters in Japan, has agreed to pay a potential $250 million in a deal for Neurovance, a company specialising in treatments for patients with AD...

Otsuka Pharmaceutical to acquire Neurovance

Otsuka Pharmaceutical Co. (OPC) has agreed to acquire Neurovance, a privately held, venture-funded, clinical stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and...

Otsuka acquires private CNS company Neurovance for up to $250mm

Otsuka Pharmaceutical Co. Ltd. acquired private attention-deficit hyperactivity disorder (ADHD)-focused biotech Neurovance Inc.

Otsuka acquires ADHD drug in $100M deal for Neurovance

The Japanese pharma has focused on CNS as a core therapeutic area, and the takeover of Neurovance will add a Phase 3-ready ADHD drug to its pipeline. 

Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline

Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile...  

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Neurovance Inc.

Neurovance is a neuroscience-focused, clinical-stage biopharmaceutical company that specializes in triple reuptake inhibitors specifically optimized for adult attention deficit hy...

Neurovance, Inc.

Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurov...

More Information about "Neurovance, Inc." on BioPortfolio

We have published hundreds of Neurovance, Inc. news stories on BioPortfolio along with dozens of Neurovance, Inc. Clinical Trials and PubMed Articles about Neurovance, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neurovance, Inc. Companies in our database. You can also find out about relevant Neurovance, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...


Corporate Database Quicklinks



Searches Linking to this Company Record